Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.51 |
| ▸ | CDC25B | P30305 | 8/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.51 |
| ▸ | TACR2 | P21452 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16967451 | 0.91 | TP53 (0.55) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL5840927 | 0.91 | TP53 (0.55) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL5840884 | 0.91 | TP53 (0.55) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL15514084 | 0.91 | TP53 (0.55) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL12812854 | 0.90 | NT5E (0.51) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL7582210 | 0.88 | TP53 (0.55) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL11173059 | 0.87 | TP53 (0.52) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL13491599 | 0.86 | POLB (0.52) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL7583524 | 0.86 | POLB (0.52) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL16628842 | 0.86 | L3MBTL1 (0.58) | NT5EPTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073589-A1 | Amphetamine Prodrugs | SHIRE AG (CH) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073589-A1 | Amphetamine Prodrugs | SLC6A2, SLC6A3, TAAR5 | NT5E 894/4885PTPN1 1433/4885CDC25B 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.